Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome

Association Between Baseline Therapy and Flare Reduction in Mepolizumab-Treated Patients With Hypereosinophilic Syndrome

BackgroundCurrent standard-of-care treatments for hypereosinophilic syndrome (HES) include oral corticosteroids (OCS) and immunosuppressive/cytotoxic (IS/CT) therapies. The anti-IL-5 monoclonal antibody mepolizumab has also recently been approved for patients with this disease. The objective of this...

Descripció completa

Dades bibliogràfiques
Autors principals: Andreas Reiter, Guillaume Lefevre, Maria C. Cid, Namhee Kwon, Eleni Mavropolou, Steven W. Yancey, Jonathan Steinfeld
Format: Article
Idioma:English
Publicat: Frontiers Media S.A. 2022-04-01
Col·lecció:Frontiers in Immunology
Matèries:
hypereosinophilic syndrome
eosinophils
clinical immunology
mepolizumab
oral corticosteroids
immunosuppressive therapy
Accés en línia:https://www.frontiersin.org/articles/10.3389/fimmu.2022.840974/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.840974/full

Ítems similars